1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €17.26 (+144.82%). The median is €17.26 (+144.82%).
| Buy |
10 |
| Hold |
2 |
| Sell |
4 |
News Go to news feed
Rockwell Medical expects smaller loss and revenue increase for quarter ended 30 June 2026
Rockwell Medical will release results for the quarter ended 30 June 2026 on 13 August 2026. Two analysts estimate an average EPS of -$0.235 (prior year -$0.500) and revenue of $17.8 million (+10.9% versus $16.1 million). For the current fiscal year the same analysts forecast an EPS of -$0.880 and revenue of $72.5 million (prior year $69.3 million). » More on finanzen.net
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 15.58M | 14.26% |
| Gross profit | 2.84M | 33.81% |
| Net profit | -1.03M | 18.87% |
| EBITDA | -349.61K | 36.90% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €27.83M |
Number of shares | 3.95M |
52-week high/low | €18.13 - €4.22 |
| Dividends | No |
Beta | 1.62 |
P/E ratio | -5.88 |
PEG ratio | 0.03 |
P/B ratio | 0.92 |
P/S ratio | 0.46 |
Company profile
| Name | Rockwell Medical |
| CEO | Mark Strobeck |
| Employees | 157 |
Discover assets
Shareholders of Rockwell Medical also invest in the following assets
